Seres Therapeutics (MCRB) Receiving Somewhat Positive Media Coverage, Analysis Shows

Media headlines about Seres Therapeutics (NASDAQ:MCRB) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seres Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.715506766933 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MCRB opened at $7.90 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.90 and a quick ratio of 4.90. Seres Therapeutics has a 1 year low of $6.65 and a 1 year high of $17.42. The stock has a market cap of $313.40, a PE ratio of -3.57 and a beta of 0.51.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. The business had revenue of $3.06 million during the quarter, compared to analysts’ expectations of $3.00 million. sell-side analysts forecast that Seres Therapeutics will post -2.64 EPS for the current year.

MCRB has been the subject of a number of research reports. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.00.

ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics (MCRB) Receiving Somewhat Positive Media Coverage, Analysis Shows” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/13/seres-therapeutics-mcrb-receiving-somewhat-positive-media-coverage-analysis-shows.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply